Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma,
is clinically heterogeneous: 40% of patients respond well to current therapy and have …

A role for B-cell-receptor (BCR) signalling in lymphomagenesis has been inferred by studying
immunoglobulin genes in human lymphomas 1 , 2 and by engineering mouse models 3 , …

Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high
efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less than …

The most common human leukemia is B cell chronic lymphocytic leukemia (CLL), a malignancy
of mature B cells with a characteristic clinical presentation but a variable clinical course. …

Gene expression profiling has revealed that diffuse large B cell lymphoma (DLBCL) consists
of at least two distinct diseases. Patients with one DLBCL subtype, termed activated B cell–…

Gene-expression profiling has been used to define 3 molecular subtypes of diffuse large B-cell
lymphoma (DLBCL), termed germinal center B-cell-like (GCB) DLBCL, activated B-cell-…

The presence or absence of somatic mutations in the expressed immunoglobulin heavy chain
variable regions (IgVH) of chronic lymphocytic leukemia (CLL) cells provides prognostic …

Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma.
In the least curable (ABC) subtype of DLBCL, survival of the malignant cells is dependent …

Mechanisms of constitutive NF-κB signaling in multiple myeloma are unknown. An inhibitor
of IκB kinase β (IKKβ) targeting the classical NF-κB pathway was lethal to many myeloma cell …

Immune checkpoint blockade represents a major breakthrough in cancer therapy; however,
responses are not universal. Genomic and immune features in pretreatment tumor biopsies …